IMATINIB
Traitement de patients adultes et pédiatriques atteints d'une leucémie myéloïde Ph+ chronique (LMC Ph+) en …
Additional information from the official database
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
400.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
478.0 MG | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | FTODK |
|
(N/A)
|
- | Substance | FTODK |
8500 Frauenfeld